Everything below concerns melanocortin analogue. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography combined with mass spectrometry. A gradient of water and acetonitrile containing trifluoroacetic acid is a common mobile phase, and ultraviolet detection near 214 nanometres responds to the peptide backbone. Mass spectrometry confirms the expected molecular mass and helps reveal truncation or oxidation products. Purity is reported as a peak-area percentage, a figure that depends on the wavelength and gradient used, so values from different laboratories are not always directly comparable. Peptide mapping and amino acid analysis provide additional confirmation when required.
Regulatory status varies by jurisdiction, where approved prescription products, compounded preparations and research-grade material are treated as distinct categories with different documentation requirements. Suppliers of research material commonly issue a certificate of analysis listing purity, identity and sometimes endotoxin content. Independent verification by a third-party laboratory is often recommended because self-reported figures are difficult to check. Literature discussions usually state the source, purity and storage conditions of the material used, since these details affect reproducibility. Analysts note that a reported purity figure does not by itself describe biological activity.
Lyophilised peptide is generally held below minus twenty degrees Celsius, protected from light and moisture, because hydrolysis and oxidation accumulate faster at ambient temperature. Once reconstituted, solutions are typically kept between two and eight degrees Celsius and used within a short window defined by the supplier. Repeated freeze-thaw cycles are avoided since they promote aggregation and loss of soluble material. Container material matters as well, because peptides adsorb to certain plastics and glass surfaces at low concentration. Stability figures supplied by a vendor apply only to the specific lot and buffer that were tested.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Cyclic heptapeptide backbone |
| Molecular mass | Approximately 1025 Da | Nominal mass of the free peptide |
| Appearance | White to off-white lyophilised powder | Typical for purified synthetic peptides |
| Solubility class | Freely soluble in water | Organic solubility is limited |
| Typical storage temperature | −20 °C or below | Protect from moisture and light |
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
== Further reading == "Becker Muscular Dystrophy (for Parents)." Edited by Mena T. Scavina, KidsHealth, The Nemours Foundation, Mar. 2018, kidshealth.org/en/parents/becker-md.html. Gaudio, Daniela del; Yang, Yaping; Boggs, Barbara A.; Schmitt, Eric S.; Lee, Jennifer A.; Sahoo, Trilochan; Pham, Hoang T.; Wiszniewska, Joanna; Craig Chinault, A.; Beaudet, Arthur L.; Eng, Christine M. (September 2008). "Molecular diagnosis of Duchenne/Becker muscular dystrophy: enhanced detection of dystrophin gene rearrangements by oligonucleotide array-comparative genomic hybridization". Human Mutation. 29 (9): 1100–1107. doi:10.1002/humu.20841. PMID 18752307. S2CID 21437006. Li, Xihua; Zhao, Lei; Zhou, Shuizhen; Hu, Chaoping; Shi, Yiyun; Shi, Wei; Li, Hui; Liu, Fang; Wu, Bingbing; Wang, Yi (2015). "A comprehensive database of Duchenne and Becker muscular dystrophy patients (0–18 years old) in East China". Orphanet Journal of Rare Diseases. 10 (1): 5. doi:10.1186/s13023-014-0220-7. PMC 4323212. PMID 25612904.
== Use and effects == In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists DOPR's dose as 2.5 to 5 mg orally and its duration as 20 to 30 hours. It is said to have a very slow onset. The effects of DOPR have been reported to include closed-eye imagery, visuals, thinking changes, and insomnia and sleep disruption, among others. In one of the reports, it was described as a "heavy duty psychedelic", including strong and unignorable visuals.
==== ILDs related to alveolar surfactant region ==== Surfactant protein B deficiency (mutations in SFTPB) Surfactant protein C deficiency (mutations in SFTPC) ABCA3 deficiency (mutations in ABCA3) Brain–lung–thyroid syndrome (Mutations in TTF1) Congenital pulmonary alveolar proteinosis (mutations in CSFR2A and/or CSFR2B)
Increasingly, Zolpidem is being used off-label for the treatment of comatose or vegetative states for brain injuries originating outside of the brain stem. Additionally, it has been implicated in the treatment of aphasia after hypoxic stroke. While the full mechanism is currently unknown, GABA stimulation appears to create paradoxical excitement in the brain, leading to a gradual recovery of cognitive, speech, and motor function. As of 2026, the usage of Zolpidem for this purpose is scattered but has gradually increased since the breakthrough study published in 2007.
Sources: en.wikipedia.org
=== Bacterial pathogenicity === Bacteria proteins, also known as effectors, have been shown to use AMPylation. Effectors such as VopS, IbpA, and DrrA, have been shown to AMPylate host GTPases and cause actin cytoskeleton changes. GTPases are common targets of AMPylators. Rho, Rab, and Arf GTPase families are involved in actin cytoskeleton dynamics and vesicular trafficking. They also play roles in cellular control mechanisms such as phagocytosis in the host cell. The pathogen enhances or prevents its internalization by either inducing or inhibiting host cell phagocytosis. Vibrio parahaemolyticus is a Gram-negative bacterium that causes food poisoning as a result of raw or undercooked seafood consumption in humans. VopS, a type III effector found in Vibrio parahaemolyticus, contains a Fic domain that has a conserved HPFx(D/E)GN(G/K)R motif that contains a histidine residue essential for AMPylation. VopS blocks actin assembly by modifying threonine residue in the switch 1 region of Rho GTPases. The transfer of an AMP moiety using ATP to the threonine residue results in steric hindrance, and thus prevents Rho GTPases from interacting with downstream effectors. VopS also adenylates RhoA and cell division cycle 42 (CDC42), leading to a disaggregation of the actin filament network. As a result, the host cell's actin cytoskeleton control is disabled, leading to cell rounding. IbpA is secreted into eukaryotic cells from H. somni, a Gram-negative bacterium in cattle that causes respiratory epithelium infection. This effector contains two Fic domains at the C-terminal region.
=== Vertical transmission === In the case of some diseases such as AIDS and hepatitis B, it is possible for the offspring of infected parents to be born infected. This transmission of the disease down from the mother is referred to as vertical transmission. The influx of additional members into the infected category can be considered within the model by including a fraction of the newborn members in the infected compartment.
Parliament passes the Electoral Amendment Act 2025, which tightens the timeframe for voter registration, bans prisoners from voting, and allows larger anonymous political donations. 17 December: Assistant Commissioner Mike Pannett is appointed as Deputy Police Commissioner. The New Zealand Government agrees to return 3,068 hectares in the upper South Island, including the Kaiteriteri Recreation Reserve and the Abel Tasman Coast Track, plus a $420 million compensation, to Te Tau Ihu Māori as part of the Nelson Tenths settlement. Former Deputy Police Commissioner Jevon McSkimming is sentenced to nine months of home detention after pleading guilty to charges of possessing objectionable material. Primary school teachers affiliated with the New Zealand Educational Institute reject the Government's pay off of a 4.6% pay rise over the next two years. Justice Michele Wilkinson-Smith of the Wellington High Court rules in favour of PATHA's bid to delay an incoming ban on new puberty blocker prescriptions expected to come into effect on 19 December, pending a judicial review. Justice Pheroze Jagose of the Auckland High Court dismisses food processing company Talley's Group's defamation case against broadcaster TVNZ and journalist Thomas Mead over a 2021 story covering its Ashburton plant. One new case of measles is reported in Queenstown, bringing the total number of cases nationwide to 32. Four cases were active at the time.
== N == N-acetylaspartate (NAA) A molecule found predominantly in neurons, often measured via magnetic resonance spectroscopy as a marker of neuronal health and density. Narcolepsy A neurological disorder characterized by excessive daytime sleepiness, sudden sleep attacks, and sometimes cataplexy. It involves dysfunction in the brain's regulation of sleep–wake cycles. Nasal cavity The air passageway behind the nose that houses the olfactory epithelium, which contains sensory neurons responsible for detecting odors. Neocortex The largest part of the cerebral cortex, involved in higher-order brain functions such as sensory perception, motor commands, reasoning, and language. Neologism A newly coined word or expression. In neuropsychology, may refer to nonsensical or made-up words produced by individuals with certain types of aphasia. Neostriatum A subdivision of the basal ganglia comprising the caudate nucleus and putamen. It is involved in motor control and reward processing. Neural crest A group of embryonic cells that gives rise to various structures, including peripheral neurons, glia, and parts of the face and skull. Neural oscillation Rhythmic or repetitive electrical activity in the central nervous system, often observed as brain waves in EEG recordings. Neural plasticity The ability of the nervous system to change its structure and function in response to experience, injury, or development. Neural stem cell A self-renewing progenitor cell capable of generating neurons and glial cells.
It also accepted bets on horse racing and ran 4-Digits (4D) draws. In 1968, Singapore Pools was incorporated to curb illegal gambling in Singapore. It provided Singaporeans with a legal avenue to bet on lotteries, countering the rampant illegal betting syndicates that were present. On 18 April 2005, during a parliament session, Prime Minister of Singapore Lee Hsien Loong announced the cabinet's decision to develop two casinos and associated hotels and malls in Marina South and Sentosa. Prior to the development of the integrated resorts, locals would primarily gamble on cruise ships that sailed in the international waters just beyond Singapore's control or travel to Genting Highlands, Malaysia to gamble. These cruising casinos remained a draw to those who were deterred by the entry fee for the casinos in Singapore. The government stated that the aim of the project was to boost Singapore's tourism industry which had been facing intense competition from other destinations around the region, particularly from nearby Bangkok and Hong Kong, which has since also considered legalization of casinos in the wake of initiatives in Singapore. Even closer to home, Malaysia has long had a legal casino accompanied theme park on Genting Highlands, which proved popular with Singaporean tourists. The IRs in Singapore were expected to create about 35,000 jobs directly and indirectly. In addition to the casinos, the IRs will have other amenities including hotels, restaurants, shopping and convention centers, theatres, museums and theme parks.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide that acts as an agonist at melanocortin receptors. It is not a hormone replacement therapy and not a vasodilator in the usual clinical sense, although it does affect vascular tone. Chemically it belongs to the melanocortin analogue family.
PT-141 was the internal development code used during early research and it persists in older publications, conference abstracts, and informal listings. The code and the approved name refer to the same molecule. Its continued use reflects habit in the literature rather than any difference in substance.
No. The intranasal form was studied in trials but was never approved, and absorption through the nasal route varies considerably between individuals. Approved labelling covers a subcutaneous injection only. Any nasal product sold outside regulated channels falls outside verified manufacturing.
Purity is normally expressed as a percentage of total peak area from a chromatographic run. The value depends on the column, gradient and detection wavelength chosen. Results generated under different conditions are therefore not always interchangeable.